DK0626853T3 - Anvendelse af substituerede adeninderivater til behandling af multipel sclerose - Google Patents

Anvendelse af substituerede adeninderivater til behandling af multipel sclerose

Info

Publication number
DK0626853T3
DK0626853T3 DK93906071T DK93906071T DK0626853T3 DK 0626853 T3 DK0626853 T3 DK 0626853T3 DK 93906071 T DK93906071 T DK 93906071T DK 93906071 T DK93906071 T DK 93906071T DK 0626853 T3 DK0626853 T3 DK 0626853T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
treatment
adenine derivatives
substituted adenine
formula
Prior art date
Application number
DK93906071T
Other languages
Danish (da)
English (en)
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of DK0626853T3 publication Critical patent/DK0626853T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK93906071T 1992-02-19 1993-02-18 Anvendelse af substituerede adeninderivater til behandling af multipel sclerose DK0626853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
DK0626853T3 true DK0626853T3 (da) 2000-08-07

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93906071T DK0626853T3 (da) 1992-02-19 1993-02-18 Anvendelse af substituerede adeninderivater til behandling af multipel sclerose

Country Status (15)

Country Link
US (4) US5310732A (de)
EP (1) EP0626853B1 (de)
JP (1) JP2688113B2 (de)
AT (1) ATE192045T1 (de)
AU (1) AU682818B2 (de)
BR (1) BR9305907A (de)
CA (1) CA2130275C (de)
CH (1) CH684310A5 (de)
DE (1) DE69328474T2 (de)
DK (1) DK0626853T3 (de)
FI (1) FI943805L (de)
HU (1) HU218656B (de)
NO (2) NO309025B1 (de)
RU (1) RU2130308C1 (de)
WO (1) WO1993016706A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
EP0642347A4 (de) * 1992-05-19 1997-06-18 Scripps Research Inst Verwendung von 2-halo-adeninderivaten als therapeutische wirkstoffe gegen chronisch-myeloische leukämie.
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US7094597B1 (en) 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
AU7470794A (en) * 1994-05-26 1995-12-21 Scripps Research Institute, The 2-halo-2'-deoxyadenosine treatement for inflammatory bowel disease
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5817641A (en) * 1994-07-21 1998-10-06 Thomas Jefferson University Treatment of enterotoxigenic diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
ES2182920T3 (es) * 1994-12-22 2003-03-16 Ortho Pharma Corp Formulaciones solubles de 2-cloro02'-deoxiadenosina.
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
SK283821B6 (sk) * 1995-02-10 2004-02-03 Schering Aktiengesellschaft Farmaceutické preparáty na inhibíciu tumornekrózafaktora
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
ATE332910T1 (de) * 2000-02-18 2006-08-15 Southern Res Inst Verfahren zur herstellung von 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofura osyl)-9h-purin-6-amin
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EA005821B1 (ru) 2000-11-01 2005-06-30 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
EP1549141A4 (de) * 2002-09-27 2008-06-25 Bioenvision Inc Verfahren und zusammensetzungen für die behandlung von autoimmunerkrankungen unter verwendung von clofarabin
EP1551386A4 (de) * 2002-09-27 2009-03-25 Bioenvision Inc Verfahren und zusammensetzungen zur behandlung von lupus mit clofarabin
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
ES2409884T3 (es) * 2003-03-28 2013-06-28 Ares Trading S.A. Formulaciones orales de cladribina
HRP20050924A2 (en) * 2003-03-28 2006-08-31 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
WO2005009971A1 (ja) * 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
DE602004006895T2 (de) * 2003-12-29 2008-01-31 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
EP3332789B1 (de) * 2004-12-22 2022-04-06 Merck Serono SA Cladribinkur zur behandlung von multipler sklerose
JP2008524310A (ja) * 2004-12-22 2008-07-10 ラボラトワール セローノ ソシエテ アノニム 多発性硬化症の組み合せ治療
CA2595126A1 (en) * 2005-01-14 2006-07-20 The Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2030615A3 (de) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
EP3608022A1 (de) 2013-03-15 2020-02-12 The Trustees of Princeton University Verfahren und vorrichtungen für reinigung mit hohem durchsatz
EP3569313A1 (de) 2013-03-15 2019-11-20 GPB Scientific, LLC Mikrofluidische on-chip-verarbeitung von partikeln
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
JP2017534627A (ja) 2014-11-06 2017-11-24 ノースウエスタン ユニバーシティＮｏｒｔｈｗｅｓｔｅｒｎ Ｕｎｉｖｅｒｓｉｔｙ 癌細胞運動性の阻害
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
HK1250543A1 (zh) * 2015-08-24 2018-12-21 日本瑞翁株式会社 用於多步骤细胞纯化和浓缩的方法和装置
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
EP3713582A1 (de) 2017-11-24 2020-09-30 Merck Patent GmbH Cladribin-dosierungsplan zur verwendung bei der behandlung progressiver formen von multipler sklerose
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
US20240077481A1 (en) 2021-03-03 2024-03-07 Ares Trading S.A. Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572070C3 (de) * 1966-03-12 1979-03-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Kopiermaterial
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
EP0314011A3 (de) * 1987-10-30 1990-04-11 F. Hoffmann-La Roche Ag Purinderivate
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
JP3090456B2 (ja) * 1988-03-16 2000-09-18 スクリップス クリニック アンド リサーチ ファウンデーション 治療剤として有用な置換アデニン誘導体
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
DE69328474T2 (de) 2000-09-28
EP0626853A1 (de) 1994-12-07
ATE192045T1 (de) 2000-05-15
HU218656B (hu) 2000-10-28
NO322328B1 (no) 2006-09-18
US5310732A (en) 1994-05-10
JPH07507540A (ja) 1995-08-24
JP2688113B2 (ja) 1997-12-08
CH684310A5 (de) 1994-08-31
US5506214A (en) 1996-04-09
US5506213A (en) 1996-04-09
US5541164A (en) 1996-07-30
WO1993016706A1 (en) 1993-09-02
CA2130275C (en) 1999-06-29
EP0626853B1 (de) 2000-04-26
AU3724993A (en) 1993-09-13
RU2130308C1 (ru) 1999-05-20
HUT68030A (en) 1995-05-29
NO20000762D0 (no) 2000-02-16
BR9305907A (pt) 1997-10-21
NO20000762L (no) 1994-09-13
AU682818B2 (en) 1997-10-23
NO942765L (no) 1994-09-13
NO942765D0 (no) 1994-07-25
FI943805A7 (fi) 1994-10-19
FI943805L (fi) 1994-10-19
FI943805A0 (fi) 1994-08-18
HU9402392D0 (en) 1994-10-28
RU94038043A (ru) 1996-11-20
NO309025B1 (no) 2000-12-04
DE69328474D1 (de) 2000-05-31
CA2130275A1 (en) 1993-09-02

Similar Documents

Publication Publication Date Title
DK0626853T3 (da) Anvendelse af substituerede adeninderivater til behandling af multipel sclerose
ATE245646T1 (de) Therapeutische nukleoside
RU95113454A (ru) Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения
NO990708D0 (no) Bisykliske pyrimidinderivater og deres anvendelse som antikoagulanter
DE69109125D1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
ES2067314T3 (es) 3-benzacepin-zonas sustituidas por un grupo benzociclobutilo o indanil-alquil-amino-alquilo, utiles en el tratamiento de las afecciones cardiovasculares.
ATE251141T1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
ES2193252T3 (es) Quinolonas y su uso terapeutico.
FI895447A0 (fi) Substituerade adeninderivat anvaendbara som terapeutiska substanser.
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
DK0565631T3 (da) Antivirale forbindelser
DK0710239T3 (da) Nye 9-N-bicycliske nucleosidmidler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
DK190983A (da) 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
YU4393A (sr) Supstituisani heksahidroazepinoni i tetrahidrobenzazepinoni
DE69418050D1 (de) Antivirale analoge von difluorostaton
SU1279221A1 (ru) 3-Метил-1-(4-тиоцианатофенил)-5-(2-фурил-)-Δ-пиразолин, проявляющий противовоспалительную активность